Apple Watch Irregular Rhythm Alert Survey

Physician Responses to Apple Watch-Detected Irregular Rhythm Alerts: A Case-Based Survey

Patrick C. Demkowicz,^{1,2,3} Sanket S. Dhruva,⁴ Erica S. Spatz,^{2,3} Alexis L. Beatty,^{4,5} Joseph S. Ross,^{1,3,6} Rohan Khera^{*2,3,7}

- 1. Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
- 2. Section of Cardiology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
- 3. Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, CT
- 4. Division of Cardiology, Department of Medicine, University of California San Francisco (UCSF), San Francisco, CA
- 5. Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA
- 6. Department of Health Policy and Management, Yale School of Public Health
- 7. Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT

Presentations: Poster at the 2022 American Heart Association Quality of Care and Outcomes Research (AHA QCOR) Scientific Session (Abstract 43).

Correspondence To:

Rohan Khera, MD, MS 195 Church St, 5th Floor, New Haven, CT 06510 203-764-5885; rohan.khera@yale.edu; @rohan_khera

Abstract: 243 words Main Text: 3034 words Number of Tables/Figures: 2 tables and 4 figures (4 tables and 1 figure in the supplement)

Apple Watch Irregular Rhythm Alert Survey

1 ABSTRACT

2 Background: While the US Food and Drug Administration (FDA) has cleared smart watch

3 software for detecting atrial fibrillation (AF), there is lack of guidance on management by

4 physicians.

5 **Methods:** We conducted a case-based survey of physicians in primary care, emergency

6 medicine, and cardiology at Yale and University of California San Francisco from September to

7 December 2021. Cases described asymptomatic patients receiving Apple Watch AF alerts;

8 cases varied in sex, race, medical (diabetes and hypertension) history, and notification

9 frequency. Physicians were asked to select from among prespecified diagnostic testing, referral,

10 and treatment options.

11 **Results:** We emailed 636 physicians, of whom 95 (14.9%) filled out the survey, including 39

12 primary care, 25 emergency medicine, and 31 cardiology physicians. Among a total of 192

13 cases (16 unique scenarios), physicians selected at least one diagnostic test in 191 (99.5%)

14 cases and medications in 48 (25.0%). Rates of patient referral (14%, 30%, and 16%,

respectively; P=.048), rhythm monitoring (84%, 46%, and 94%, respectively; P<.001),

16 measurement of BNP (8%, 20%, and 2%; P=.003), and use of antiarrhythmics (16%, 4%, and

17 23%; P=.023) varied among primary care, emergency medicine, and cardiology, respectively.

18 Management was largely consistent across case characteristics (race, sex, medical history, and

19 alert frequency).

20 **Conclusion**: In hypothetical cases of patients presenting without clinical symptoms, physicians

21 opted for further diagnostic testing and often to medical intervention based on Apple Watch

22 irregular rhythm notifications. There was also considerable variation across physician

23 specialties, suggesting a need for uniform clinical practice guidelines.

Apple Watch Irregular Rhythm Alert Survey

25 BACKGROUND

Several medical and public health bodies do not recommend widespread screening for 26 27 atrial fibrillation (AF). The US Preventative Services Task Force determined in 2022 that current 28 evidence is insufficient to determine balance of benefits and harms of ECG screening among 29 asymptomatic adults.¹ Screening for AF has not been demonstrated to reduce stroke risk.²⁻⁴ 30 Conversely, healthy patients who falsely screen positive may receive unnecessary and potentially harmful testing and treatment.^{5,6} Despite such evidence, there is widespread interest 31 32 in screening for AF with the goal of reducing stroke mortality and morbidity. The FDA has 33 cleared smart watch applications that can identify irregular rhythms, such as AF, regardless of 34 whether the patient experiences clinical symptoms, including recent versions of the Apple Watch and Fitbit.^{7,8} Some devices also have single-lead ECG functionalities that clinicians may 35 36 manually review. However, there is no evidence that medical evaluation for irregular rhythms 37 detected by smart watches improves patient morbidity or mortality.

38 Despite a lack of established benefits of wearable screening for AF, smart watches have 39 grown in popularity with 1% of primary care patients having documentation of a device in a recent study of an academic health care system.⁹ Clinical encounters where patients discuss 40 information generated from smart watches are challenging for physicians given the lack of 41 42 clinical evidence to inform decision-making, clinical practice guidelines regarding asymptomatic 43 AF screening, and consensus strategies for clinical evaluation for these patients. Furthermore, different device companies' algorithms vary in their diagnostic yield.¹⁰ Recent surveys have 44 45 found that cardiac electrophysiologists would consider pursuing further electrophysiological 46 evaluation as well as initiate anticoagulation in asymptomatic patients on the basis of smart 47 watch irregular rhythm and single-lead ECG findings despite lack of any evidence to suggest benefit of such an approach.^{11,12} These findings suggest that there is substantial variation in the 48 49 strategies adopted by different clinicians.

Apple Watch Irregular Rhythm Alert Survey

50	On the other hand, widespread availability of smart watches may instead increase rates
51	of AF diagnosis among marginalized patients, mitigating current disparities in care. For
52	example, Black patients with AF are less likely than White patients to receive a formal diagnosis
53	and receive anticoagulation. ¹³ Female patients with AF are less often prescribed anticoagulation
54	therapy despite having higher stroke risk. ¹⁴ Furthermore, a study using hypothetical case
55	histories found gender bias in attitude toward and secondary prevention of patients with
56	coronary artery disease. ¹⁵ A study using actors portraying patients with chest pain found that
57	women and Black adults were less likely to be referred for cardiac catheterization than men and
58	White adults. ¹⁶
59	In this study, we used hypothetical patient cases to conduct a multicenter evaluation of
60	physicians' responses to asymptomatic patients reporting Apple Watch irregular rhythm
61	notifications suggestive of AF. We sought to evaluate variation across physicians and assess
62	whether specialty and personal experience with smart watches influenced their approach to
63	management. We also assessed whether patient characteristics influenced the approach of
64	physicians to patient-reported episodes of Apple Watch-detected, asymptomatic AF.
65	
66	METHODS
67	Study Population
68	We conducted a cross-sectional, case-based survey of attending and resident
69	physicians practicing in primary care, emergency medicine, and cardiology departments at two
70	geographically separated health systems, (1) Yale New Haven Hospital in New Haven,
71	Connecticut and, (2) University of California San Francisco between September and December
72	2021. Respondents' department affiliations and email addresses were gathered from their
73	institutional directory profiles, if available. Our study was exempted from review by the Yale and
74	UCSF institutional review boards.
75	Survey Design

Apple Watch Irregular Rhythm Alert Survey

76 The survey was developed by 2 cardiologists, an internist, and a medical student, and reviewed by 2 other cardiologists. The survey is included in Supplement 1 and the Consensus-77 Based Checklist for Reporting of Survey Studies (CROSS) is included in Supplement 2.¹⁷ The 78 79 survey consisted of two clinical vignettes. Each vignette involved a 60-year-old person who 80 reported recently receiving one or more irregular rhythm notifications on their Apple Watch in 81 the absence of associated symptoms (i.e., no fatigue or racing sensation in his chest). Four 82 variables varied across the 16 scenarios: stroke risk-factors (none or history of diabetes and 83 hypertension), reported frequency of recent alerts (1 or >1), sex (male or female) and race 84 (Black or White). The atrial fibrillation stroke risk factors represent items on the CHAD₂DS₂-VASc score.¹⁸ 85 86 Respondents were randomized by the survey platform to see one low stroke-risk case

87 and one moderate-high stroke-risk case of two patients with the same race and sex. Due to an 88 error in the survey platform settings, 5 respondents completed a third case that varied from their 89 second case with respect to alert frequency. A respondent notified the team of the error and it 90 was promptly corrected. Respondents were then asked to rate on a five-point Likert scale the 91 likelihood that they would consider specific diagnostic evaluations and therapeutic interventions. 92 Next, respondents were asked on a five-point Likert scale how important (extremely, very 93 moderately, slightly, not at all) various factors were in determining their answer choices in the 94 preceding cases: likelihood of AF in patient's group, risk of stroke in patient's group, strength of 95 evidence, concern about missing a diagnosis, and concern about unnecessary testing. Finally, 96 respondents were asked about their own backgrounds and practices. We asked respondents 97 about their gender, race, specialty, training history, personal use of smart watches capable of 98 rhythm detection, and experience recommending smart watches to their patients.

99 Survey Delivery

We used Qualtrics to host our survey and send email invitations. Qualtrics generated a
unique invitation link for each respondent. This allowed us to track survey completion and

Apple Watch Irregular Rhythm Alert Survey

102 prevent multiple participation. Completed responses were deidentified by Qualtrics. Respondents at Yale were emailed three weekly reminders and respondents at UCSF 2 103 104 reminders (1 and 3 weeks) if they did not respond. Respondents were shown an information 105 sheet about the survey before consenting to participate. They were then offered the opportunity 106 to enter a drawing for a \$100 gift card. To begin the survey, respondents were required to 107 consent to participate and then select their specialty before they could advance to the case 108 scenarios. Respondents who did not complete this step or who left all case questions 109 unanswered were excluded.

110 Outcomes

111 The primary outcome was the proportion of responses indicating the use of specific

interventions. These included: referring to primary care, cardiology, or electrophysiology;

113 ordering a cardiovascular stress test, 12-lead ECG, serum brain natriuretic peptide (BNP),

114 transthoracic echocardiogram, ambulatory rhythm monitoring (specific options included event

115 monitor, implantable loop recorder, patch monitor, or a commercially available heart rhythm

116 monitor such as AliveCor, which were combined into one category); and treating with aspirin,

anticoagulation, a beta blocker or calcium channel blocker, or a class IC or III antiarrhythmic.

118 We categorized the responses as "yes" and "no", combining responses of "Extremely Likely" or

119 "Somewhat Likely" into a yes category and responses of "Neither Likely nor Unlikely,"

120 "Somewhat Unlikely," and "Extremely Unlikely" into a no category.

121 Statistical Analyses

We generated descriptive statistics (specialty, sex, age, and years in practice) about our study population using percentages to report categorical variables and averages (standard deviation) to report continuous variables, stratified by respondent specialty. We also reported rates of different categories of experiences with smart watches (personal use, having previously recommended patients use wearable devices, and having experienced a patient reporting

Apple Watch Irregular Rhythm Alert Survey

results from a smart watch) stratified by respondent specialty. We used the chi-squared test tocompare rates across specialties.

129 We reported the rates at which specific tests and interventions were selected. Because 130 respondents evaluated multiple cases, we calculated mean rates out of all, non-unique cases. 131 We also used a histogram distribution to report the number of diagnostic tests (stress test, 12-132 lead ECG, serum BNP, TTE, ambulatory rhythm monitoring), or medical interventions (aspirin, 133 anticoagulation, antiarrhythmic) that were selected across all, non-unique cases. 134 We analyzed the relationship between respondent characteristics and the likelihood with 135 which specific tests or interventions were selected. We repeated this analysis to compare 136 across years of practice (0-9, 10-19, 20+) and between respondents who did or did not report 137 different types of experiences with smart watches. We used the chi-squared test to compare 138 rates across levels of respondent characteristics (e.g., specialty). 139 We repeated the above analysis to evaluate the relationship between patient 140 characteristics and respondent's likelihood of selecting each test or intervention. We compared 141 rates of each intervention by the race (Black vs. white), sex (male vs. female), and history of 142 stroke risk factors (none vs. hypertension and diabetes) of the patient described, as well as by 143 the number of notifications reported by the patient in the scenario (one vs. many). Analyses 144 were conducted using R (version 4) and figures were generated using Prism (version 9). A 2-145 sided p value <0.05 was considered statistically significant.

146

147 **RESULTS**

148 **Study Population**

We emailed 636 physicians (excluding an additional 14 emails that bounced-back or
failed), of whom 95 (14.9%) completed the survey, including 39 primary care, 25 emergency
medicine, and 31 cardiology physicians (Table 1); 75 were based at Yale and 20 at UCSF.
Overall, 44.2% of respondents identified as female, 55.8% were aged 44 years or younger, and

Apple Watch Irregular Rhythm Alert Survey

- 40% of respondents report being practice less than a decade, with 22.1% practicing 10-19
- 154 years, and 31.6% practicing more than 20 years (6.3% missing).

155 Overall, 27 (28.4%) respondents reported personally using a smart watch, which was

- 156 consistent across specialties (P=.68) (Table 2). However, respondents of different specialties
- 157 reported considerably different experiences with smart watches in their clinical practices,
- including the rates at which they had recommended smartwatches to their patients (12.8%
- primary care, 12.0% emergency, and 41.9% cardiology; P=.003) and have had a patient report
- a smart watch alert (30.8%, 80.0%, and 80.6%, respectively; P<.001).

161 **Overall Approach to Case Scenarios**

162 Respondents completed a total of 192 cases drawn from 16 unique scenarios; 3

respondents completed 1 case, 87 respondents completed 2 cases, and 5 respondents

164 completed 3 cases. In 191 (99.5%) cases physicians selected at least one diagnostic test to

165 work-up the asymptomatic Apple Watch irregular rhythm notification: electrocardiography (185,

166 96.4%), ambulatory rhythm monitoring (148, 77.1%), transthoracic echocardiography (TTE) (63,

167 32.8%), stress testing (19, 9.9%), and brain natriuretic peptide (BNP) evaluation (17, 8.9%)

168 (Figure 1). Respondents selected an average of 2.3 diagnostic tests (standard deviation 0.97)

169 (Figure 2A). In addition, referral and treatment options were commonly selected in response to

the notification: in 36 (18.8%) cases physicians selected referral to a different specialty and in

48 (25.0%) new medication treatment, such as aspirin (35, 18.2%), antiarrhythmics (29, 15.1%),

and/or anticoagulation (18, 9.4%). Respondents selected an average of 0.4 types of medication

- 173 (standard deviation 0.8) (Figure 2B). When asked about the factors that influenced their
- answers to the cases, 50.5%, 42.1%, 56.8%, 43.2%, and 48.4% of respondents rated as very
- important or extremely important the likelihood of AF, the risk of stroke, the strength of
- 176 evidence, concern about missing a diagnosis, and concern about unnecessary testing,
- 177 respectively (Supplement 3, Table 1)
- 178 Clinician Factors and Approach to Case Scenarios

Apple Watch Irregular Rhythm Alert Survey

179	With regard to diagnostic testing, there were no statistically significant differences
180	among specialties in selection of ECG, TTE, or stress testing (Figure 3A). With regard to
181	interventions, there were no statistically significant differences among specialties in selection of
182	aspirin or anticoagulation (Figure 3B). There were significant differences among specialties in
183	rates of referral (P=.048), BNP measurement (P=.003), ambulatory rhythm monitoring (P<.001)
184	and prescription of antiarrhythmic therapy (P=.023). Years spent in practice was associated with
185	use of transthoracic echocardiogram (P=.023) and ambulatory rhythm monitoring (P<.001)
186	(Supplement 3, Figure 1).
187	Respondents who have previously recommended their patients to use smart watches
188	were more likely to order TTEs (54.8% vs. 24.8%, P<.001) and ambulatory rhythm monitoring
189	(95.2 vs. 70.2%, P=.002) (Supplement 3, Table 2). There was no relationship between other
190	respondent factors, including wearing a smart watch, having treated patients who reported
191	smart watch findings, and having recommended smart watches to patients, and selection of
192	specific interventions.

193 Simulated Patient Factors and Overall Approach to Case Scenarios

194 The distribution of case characteristics is summarized in Supplement 3, Table 3. Black race was associated with a higher receipt of antiarrhythmics (21.3% vs. 9.2%; P=.033) (Figure 195 196 4). Selection of other diagnostics and interventions were otherwise similar between cases 197 describing Black and White patients. Female sex was associated with lower use of serum BNP 198 (4.0% vs. 14.1%; P=.027). Selection of other diagnostics and interventions were otherwise similar between cases describing female and male patients. Patient stroke risk (presence vs. 199 200 absence of diabetes and hypertension) and reported frequency of alerts (single vs. repeated) 201 were not associated with differential intervention rates (Supplement 3, Table 4).

202

203 DISCUSSION

Apple Watch Irregular Rhythm Alert Survey

204 In this survey of physicians at two institutions, we used hypothetical clinical vignettes to examine decision-making patterns in response to irregular rhythm notifications on an Apple 205 206 Watch in patients without symptoms of AF. Notifications nearly always triggered further 207 diagnostic workup, varying from low-cost and low-intensity tests such as ECG to higher-cost 208 and higher-intensity procedures such as stress testing. Furthermore, in 1 out of 4 simulated 209 encounters, respondents considered initiating medications, including antiplatelet, anticoagulant, 210 and antiarrhythmic therapies on initial presentation. We found that management did not vary 211 substantially across case characteristics such as patient race, sex, stroke risk, and alert 212 frequency.

213 Our findings are consistent with prior studies that have examined clinical decision-214 making based on rhythm data from smart watches. A 4-month single-center retrospective review 215 identified 264 patients evaluated for abnormal pulse detected using Apple Watch, 33% of whom were asymptomatic.¹⁹ The study found that 61% of asymptomatic patients underwent diagnostic 216 217 testing. The study also found variation in diagnostic testing across clinical departments, with 218 patients seen in the emergency department more likely to undergo 12-lead ECG or bloodwork 219 compared with patients seen in primary care or by a cardiologist. One possible explanation for a 220 higher rate of diagnostic testing in our survey is that respondents were shown only brief 221 vignettes and not afforded the opportunity to perform a physical examination. In the 222 retrospective study, clinicians had preexisting relationships with many patients: nearly half of all 223 patients had a preexisting cardiovascular diagnosis and the most common department of 224 presentation was cardiology. Clinicians may therefore be able to work up smart watch irregular 225 rhythm notifications more conservatively in the real world than in our survey because they have 226 more data to inform decision-making.

Prior studies examining prescribing patterns in response to smart watch notifications
have focused on the interpretation of single-lead ECG tracings available on models such as the
Apple Watch 4 and later. A survey of 1601 clinicians, including advanced practice providers,

Apple Watch Irregular Rhythm Alert Survey

230 found that results from a 30-second single-lead ECG were sufficient for 42.7% of clinicians to recommend oral anticoagulation for patients at high risk for stroke.¹¹ A survey of 417 231 232 electrophysiologists worldwide found that, when presented with a single-lead ECG tracing 233 suggesting AF, 21% would consider initiating anticoagulation in an asymptomatic patient.¹² In 234 contrast, we found that respondents would consider anticoagulation approximately 9% of the 235 time in response to irregular rhythm notifications. It is expected that clinicians would be less 236 likely to consider anticoagulation on the basis of an irregular rhythm notification than a single-237 lead ECG tracing that they can manually review. Manual clinician review of single-lead ECG 238 tracings can improve the diagnostic utility of the Apple Watch automated AF-detection algorithm.¹⁰ However, it is not reasonable to initiate anticoagulation solely after a notification 239 240 because prior studies of Apple Heart Study participants found that follow-up ambulatory ECG 241 confirmed AF in 34% of cases of irregular rhythm notification, with non-AF irregular rhythms detected in 40% of cases without AF.^{20,21} 242

243 It is notable that stroke risk in our study was not associated with respondent practice 244 patterns. Researchers have advocated for screening for AF in the high-stroke risk population with the assumption that such patients would have a greater benefit.²² Our findings show that 245 246 physicians approached patients with the least potential benefit from AF screening and treatment 247 similarly to how they approached patients who would have the greatest potential benefit. This 248 suggests that in actual practice, physicians might apply such screening guidelines with a much 249 larger scope that recommended. This finding supports the concern that smart watch utilization 250 may lead to greater health care expenditure on potentially unnecessary testing and treatment.²³ 251 In patients who have true paroxysmal AF, this may also lead to disparities in access to 252 cardiovascular care between patients who own smart watches and patients who do not. 253 It is also notable that, in contrast with prior studies using simulated patients, there was

little variation in management with respect to the patient's race or sex.^{15,16} This study had fewer
 respondents and therefore may not have been sufficiently powered. Furthermore, our

Apple Watch Irregular Rhythm Alert Survey

respondent population skewed toward younger clinicians, who may have had greater exposure
to anti-bias curricula in their medical training than clinicians later than their careers.²⁴ This
finding also only looks at one mechanism – clinician bas – of systemic racism and sexism,
which may affect the outcomes of real-world patients in a myriad of ways.²⁵ Further research is
needed to understand disparities in the treatment of smart watch-detected irregular rhythms in
real world clinical practice.

262 There are several limitations to our study. First, 14.9% of physicians contacted ultimately 263 responded to our survey: respondents may have stronger attitudes toward smart watches than 264 non-respondents. We found in our survey that respondents with positive attitudes toward smart 265 watches were more likely to select certain interventions. Second, we assessed practice patterns 266 using written clinical case vignettes. It is assumed that respondents would act similarly when 267 managing actual patients.¹⁶ Furthermore, assessments made on the bases of written case 268 vignettes have been shown to correlate with those made on the basis of in-person 269 examinations. Third, our case scenarios were limited in detail and other potentially informative 270 clinical cues available in the real-world were not provided. Lastly, we surveyed physicians at two 271 large academic centers, which may limit the generalizability of our findings.

272

273 CONCLUSIONS

Our survey demonstrates that many physicians likely have a high degree of confidence in smart watch irregular rhythm notifications as demonstrated by respondents' likelihood of pursuing additional diagnostic testing and interventions. This finding raises several concerns: smart watch utilization may lead to greater health care expenditure on potentially unnecessary testing and treatment; it may also lead to disparities in access to cardiovascular care between patients who own smart watches and patients who do not. Therefore, despite the lack of recommendation by public health and professional organizations for AF screening in

Apple Watch Irregular Rhythm Alert Survey

- asymptomatic patients, our study highlights the need for further evidence to inform the
- 282 development of standardized guidelines.

283 ACKNOWLEDGEMENTS

- 284 Funding
- 285 The study was funded by the National Heart, Lung and Blood Institute (under award
- 286 K23HL153775 to RK and T35HL007649 to PD), and the Doris Duke Charitable Foundation
- 287 (under award, 2022060 to RK).

288 Author Contributions

- All authors were responsible for study concept and design; PD, RK, and SD for acquisition of
- subjects and data; PD, RK, and SD, and JR for analysis and interpretation of data; and all
- authors for preparation of manuscript.

292 COMPETING INTERESTS

293 PD reports Roivant Sciences stock options. SD reports research funding from the Department of

294 Veterans Affairs, from the Medical Device Innovation Consortium (MDIC) as part of the National

295 Evaluation System for health Technology Coordinating Center (NESTcc), Greenwall

296 Foundation, Arnold Ventures, and National Institute for Health Care Management. ES receives

grant funding from the Centers for Disease Control and Prevention (20042801-Sub01), National

- 298 Institute on Minority Health and Health Disparities (U54MD010711-01), the U.S. Food and Drug
- 299 Administration to support projects within the Yale-Mayo Clinic Center of Excellence in

300 Regulatory Science and Innovation (CERSI, U01FD005938), the National Institute of Biomedical

301 Imaging and Bioengineering (R01 EB028106-01), and from the National Heart, Lung, and Blood

- 302 Institute (R01HL151240). AB was employed by Apple Inc. 2018-2019 and held stock in Apple
- 303 Inc. 2019-2021. JR currently receives research support through Yale University from Johnson
- 304 and Johnson to develop methods of clinical trial data sharing, from the Medical Device
- 305 Innovation Consortium as part of the National Evaluation System for Health Technology

Apple Watch Irregular Rhythm Alert Survey

306	(NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence
307	in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for
308	Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood
309	Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from
310	Arnold Ventures; in addition, JR is an expert witness at the request of Relator's attorneys, the
311	Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback
312	Statute against Biogen Inc. In addition to funding listed above, RK also receives research
313	support, through Yale, from Bristol-Myers Squibb. He is a coinventor of U.S. Pending Patent
314	Application No. 63/177,117, "Methods for neighborhood phenomapping for clinical trials", and
315	U.S. Provisional Patent Application No. 63/346,610, "Articles and methods for format
316	independent detection of hidden cardiovascular disease from printed electrocardiographic
317	images using deep learning". He is also a founder of Evidence2Health, a precision health
318	platform to improve evidence-based cardiovascular care.

Apple Watch Irregular Rhythm Alert Survey

320 TABLES AND FIGURES

321

Table 1. Respondent characteristics. Respondent demographics and years in practice are presented overall and by specialty. Data were missing for 6 respondents (6.3% overall).

324

	Primary care (N=39)	Emergency medicine (N=25)	Cardiovascular/ Electrophysiology (N=31)	Overall (N=95)
Gender				
Female	24 (61.5%)	11 (44.0%)	7 (22.6%)	42 (44.2%)
Male	13 (33.3%)	13 (52.0%)	21 (67.7%)	47 (49.5%)
Age in years				
< 45	19 (48.7%)	19 (76.0%)	15 (48.4%)	53 (55.8%)
45 - 65	17 (43.6%)	5 (20.0%)	11 (35.5%)	33 (34.7%)
> 65	1 (2.6%)	0 (0%)	2 (6.5%)	3 (3.2%)
Years in Practice				
0 - 9	13 (33.3%)	17 (68.0%)	8 (25.8%)	38 (40.0%)
10 - 19	8 (20.5%)	5 (20.0%)	8 (25.8%)	21 (22.1%)
> 20	16 (41.0%)	2 (8.0%)	12 (38.7%)	30 (31.6%)

325

326

327

Apple Watch Irregular Rhythm Alert Survey

329 **Table 2. Experience with smartwatches.** Respondents' experiences with smartwatches

(personally wearing one, having had recommended one to a patient, and having encountered a
 patient reporting smartwatch alerts) are presented by specialty. Data were missing for 6

332 respondents (6.3% overall).

333

	Primary care (N=39)	Emergency medicine (N=25)	Cardiovascular/ EP (N=31)	P-value
Wears a Smartwatch				0.681
Yes	13 (33.3%)	6 (24.0%)	8 (25.8%)	
No	24 (61.5%)	18 (72.0%)	20 (64.5%)	
Has Recommended Smartwatches to Patients				0.003
Yes	5 (12.8%)	3 (12.0%)	13 (41.9%)	
No	32 (82.1%)	21 (84.0%)	15 (48.4%)	
Has Experience with Patients Reporting Smartwatch Alerts				<0.001
Yes	12 (30.8%)	20 (80.0%)	25 (80.6%)	
No	25 (64.1%)	4 (16.0%)	3 (9.7%)	

Apple Watch Irregular Rhythm Alert Survey







Figure 1. Rates of testing and intervention overall. Among 95 participants, 192 hypothetical 337 cases were completed. Here we report the average rate at which respondents indicated that 338 they were "extremely likely" or "somewhat likely" to order specific diagnostic tests, 339 referral/consultation, and therapeutic interventions. "Rhythm monitoring" indicates that any of 340 the following were selected: event monitor, implantable loop recorder, patch monitor, or a

341 commercially available heart rhythm monitor such as AliveCor. "Antiarrhythmics" included

342 selection of a beta blocker or calcium channel blocker, or a class IC or III antiarrhythmic. ECG =

343 electrocardiogram, TTE = transthoracic echocardiogram, and BNP = brain natriuretic peptide.

344







347 The number of diagnostic tests (among ECG, rhythm monitoring, TTE, stress test, and BNP)

348 and types of medications (among aspirin, antiarrhythmics, and anticoagulation) were tallied in 349 each case (N = 192). The distributions of frequencies are reported here.

Apple Watch Irregular Rhythm Alert Survey







Figure 3. Rates of testing and intervention by respondent specialty.



353 354

355 Figure 4. Rates of testing and intervention by race of simulated patient.

Apple Watch Irregular Rhythm Alert Survey

358 **REFERENCES**

359

- 360 1 Force, U. S. P. S. T. Screening for Atrial Fibrillation: US Preventive Services
- 361 Task Force Recommendation Statement. *JAMA* **327**, 360-367,
- 362 doi:10.1001/jama.2021.23732 (2022).
- 363 2 Svennberg, E., Engdahl, J. & Rosenqvist, M. Screening for Atrial Fibrillation to
- Initiate Stroke-Protective Therapy. *Am Fam Physician* **101**, 6-7 (2020).
- 365 3 Noseworthy, P. A. *et al.* Subclinical and Device-Detected Atrial Fibrillation:
- 366 Pondering the Knowledge Gap: A Scientific Statement From the American Heart
- 367 Association. *Circ* **140**, e944-e963, doi:doi:10.1161/CIR.000000000000740
- 368 (2019).
- 369 4 Svendsen, J. H. *et al.* Implantable loop recorder detection of atrial fibrillation to
- 370 prevent stroke (The LOOP Study): a randomised controlled trial. *Lancet* **398**,

371 1507-1516, doi:10.1016/S0140-6736(21)01698-6 (2021).

- 372 5 Varshney, A. S., Madias, C., Kakkar, R. & Martin, D. T. Watching for Disease: the
- 373 Changing Paradigm of Disease Screening in the Age of Consumer Health
- 374 Devices. J Gen Intern Med **35**, 2173-2175, doi:10.1007/s11606-019-05626-y
- 375 (2020).
- Mandrola, J. & Foy, A. Screening for Atrial Fibrillation—New Devices, Same
 Challenges. *JAMA Intern Med* **182**, 251-253,
- 378 doi:10.1001/jamainternmed.2021.7283 (2022).
- 379 7 Krueger, A. C. (ed Center for Devices and Radiological Health) (2018).
- 380 8 Kozen, J. S. (ed Center for Devices and Radiological Health) (2022).
- 381 9 Al-Alusi, M. A. *et al.* Trends in Consumer Wearable Devices With Cardiac
- 382 Sensors in a Primary Care Cohort. *Circ Cardiovasc Qual Outcomes* **0**,

Apple Watch Irregular Rhythm Alert Survey

- 383 10.1161/CIRCOUTCOMES.1121.008833,
- 384 doi:10.1161/CIRCOUTCOMES.121.008833.
- 385 10 Ford, C. *et al.* Comparison of 2 Smart Watch Algorithms for Detection of Atrial
- 386 Fibrillation and the Benefit of Clinician Interpretation. JACC Clin Electrophysiol 8,
- 387 782-791, doi:10.1016/j.jacep.2022.02.013 (2022).
- 388 11 Ding, E. Y. et al. Survey of current perspectives on consumer-available digital
- health devices for detecting atrial fibrillation. *Cardiovasc Digit Health J* **1**, 21-29,
- 390 doi:<u>https://doi.org/10.1016/j.cvdhj.2020.06.002</u> (2020).
- 391 12 Manninger, M. *et al.* Role of wearable rhythm recordings in clinical decision
- 392 making—The wEHRAbles project. *Clin Cardiol* **43**, 1032-1039,
- 393 doi:<u>https://doi.org/10.1002/clc.23404</u> (2020).
- 394 13 Meschia, J. F. *et al.* Racial Disparities in Awareness and Treatment of Atrial
- 395 Fibrillation. *Stroke* **41**, 581-587, doi:10.1161/STROKEAHA.109.573907 (2010).
- 396 14 Kassim, N. A., Althouse, A. D., Qin, D., Leef, G. & Saba, S. Gender differences in
- 397 management and clinical outcomes of atrial fibrillation patients. J Cardiol 69, 195-
- 398 200, doi:<u>https://doi.org/10.1016/j.jjcc.2016.02.022</u> (2017).
- 399 15 Abuful, A., Gidron, Y. & Henkin, Y. Physicians' attitudes toward preventive
- 400 therapy for coronary artery disease: Is there a gender bias? Clin Cardiol 28, 389-
- 401 393, doi:<u>https://doi.org/10.1002/clc.4960280809</u> (2005).
- 402 16 Schulman, K. A. et al. The Effect of Race and Sex on Physicians'
- 403 Recommendations for Cardiac Catheterization. *N Engl J Med* **340**, 618-626,
- 404 doi:10.1056/nejm199902253400806 (1999).

Apple Watch Irregular Rhythm Alert Survey

405	17	Sharma, A. et al. A Consensus-Based Checklist for Reporting of Survey Studies
406		(CROSS). J Gen Intern Med 36 , 3179-3187, doi:10.1007/s11606-021-06737-1
407		(2021).
408	18	Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical
409		risk stratification for predicting stroke and thromboembolism in atrial fibrillation
410		using a novel risk factor-based approach: the euro heart survey on atrial
411		fibrillation. Chest 137, 263-272, doi:10.1378/chest.09-1584 (2010).
412	19	Wyatt, K. D. et al. Clinical evaluation and diagnostic yield following evaluation of
413		abnormal pulse detected using Apple Watch. J Am Med Inform Assoc 27, 1359-
414		1363, doi:10.1093/jamia/ocaa137 (2020).
415	20	Perez, M. V. et al. Large-Scale Assessment of a Smartwatch to Identify Atrial
416		Fibrillation. <i>N Engl J Med</i> 381 , 1909-1917, doi:10.1056/nejmoa1901183 (2019).
417	21	Perino, A. C. et al. Arrhythmias Other Than Atrial Fibrillation in Those With an
418		Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart
419		Study. Circ Arrhythm Electrophysiol 14, e010063, doi:10.1161/circep.121.010063
420		(2021).
421	22	Lowres, N., Neubeck, L., Redfern, J. & Freedman, S. B. Screening to identify
422		unknown atrial fibrillation. Thromb Haemost 110, 213-222 (2013).
423	23	Wang, L. et al. Association of Wearable Device Use With Pulse Rate and Health
424		Care Use in Adults With Atrial Fibrillation. JAMA Network Open 4, e215821-
425		e215821, doi:10.1001/jamanetworkopen.2021.5821 (2021).
426	24	Ufomata, E. et al. A Policy Statement of the Society of General Internal Medicine
427		on Tackling Racism in Medical Education: Reflections on the Past and a Call to

Apple Watch Irregular Rhythm Alert Survey

- 428 Action for the Future. *J Gen Intern Med* **36**, 1077-1081, doi:10.1007/s11606-020-
- 429 06445-2 (2021).
- 430 25 Feagin, J. & Bennefield, Z. Systemic racism and U.S. health care. Soc Sci Med
- 431 **103**, 7-14, doi:<u>https://doi.org/10.1016/j.socscimed.2013.09.006</u> (2014).
- 432